Prostate cancer is the second most common form of cancer in men. Around 910,000 cases of prostate cancer were recorded in 2008, accounting for nearly 14% of all new cancer cases in men. In the same year, there were over 250,000 deaths from the disease and it is predicted that the number of cases will almost double to 1.7 million by 2030.
The FAST-PATH research programme will contribute significantly to our understanding of the mechanisms and pathology underlying this disease. OncoMark, together with their industrial partner PathXL, will use prostate cancer biomarkers to help achieve this end. Their methods will include the development of novel prostate biomarkers and imaging algorithms. Other methodologies used will include tumour identification, quantitative IHC, image search techniques and automated high-throughput imaging solutions.